|
Article Excerpt
ATLANTA, May 26 /PRNewswire-FirstCall/ -- CryoLife, Inc. , a biomaterials and biosurgical device company, announced today that positive results of its SynerGraft(R) Model #100, a bovine ureter used for arteriovenous (AV) access in dialysis patients, were presented at the Fourth International Congress of the Vascular Access Society in Berlin, Germany. The data showed freedom from infection of 94% and secondary patency of 79% at one year. The objective of the study, conducted at the Oxford Transplant Center, Churchill Hospital, in Oxford, UK, was to evaluate patency and durability of the SynerGraft Model #100 AV access device in dialysis patients where access from their own vein was not possible. Additionally, the transplanted tissue that was analyzed in the study confirmed the recellularization...
|
|
More articles from PR Newswire
Madeline Hamill Elected to World Air Holdings Board of Directors., May 26, 2005
TI CEO Rich Templeton to Speak at Bernstein and Lehman Brothers Invest..., May 26, 2005
Carrier VoIP Equipment Market Up 40% Year-over-Year., May 26, 2005
L2-L3 Ethernet Switch Market Totals $3.3B in 1Q05; L4-L7 LAN Switch Ma..., May 26, 2005
Secure Router Shipments Jump 19% in 1Q05., May 26, 2005
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
|
